Integrated evidence chain-based effectiveness evaluation of traditional Chinese medicines (Eff-iEC): A demonstration study
Addressing the enduring challenge of evaluating traditional Chinese medicines (TCMs), the integrated evidence chain-based effectiveness evaluation of TCMs (Eff-iEC) has emerged. This paper explored its capacity through a demonstration study that evaluated the effectiveness evidence of six commonly used anti-hepatic fibrosis Chinese patent medicines (CPMs), including Biejiajian Pill (BP), Dahuang Zhechong Pill (DZP), Biejia Ruangan Compound (BRC), Fuzheng Huayu Capsule (FHC), Anluo Huaxian Pill (AHP), and Heluo Shugan Capsule (HSC), using both Eff-iEC and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system. The recognition of these CPMs within the TCM academic community was also assessed through their inclusion in relevant medical documents. Results showed that the evidence of BRC and FHC received higher assessments in both Eff-iEC and GRADE system, while the assessments for others varied. Analysis of community recognition revealed that Eff-iEC more accurately reflects the clinical value of these CPMs, exhibiting superior evaluative capabilities. By breaking through the conventional pattern of TCMs effectiveness evaluation, Eff-iEC offers a novel epistemology that better aligns with the clinical realities and reasoning of TCMs, providing a coherent methodology for clinical decision-making, new drug evaluations, and health policy formulation.
Authors
- Zhijie Ma (ORCID: https://orcid.org/0000-0001-5228-3493)
- Tianyi Zhang (ORCID: https://orcid.org/0000-0003-4028-1663)
- Jinfa Tang (ORCID: https://orcid.org/0000-0001-7786-0955)
- Shuanglin Qin (ORCID: https://orcid.org/0000-0003-3022-7233)
- Aiguo Dai (ORCID: https://orcid.org/0000-0002-5371-917X)
- Jianyu Li (ORCID: https://orcid.org/0000-0002-6525-8251)
- Yang Ming (ORCID: https://orcid.org/0000-0002-6534-7959)
- Xu Zhao (ORCID: https://orcid.org/0000-0002-8420-4910)
- Jun Zhao (ORCID: https://orcid.org/0000-0001-9976-0920)
- Jia-Bo Wang
- Ping Zhang (ORCID: https://orcid.org/0000-0001-6602-1427)
- Jing Jing (ORCID: https://orcid.org/0000-0002-0899-0171)
- Ruilin Wang (ORCID: https://orcid.org/0000-0003-3773-0886)
- Xiangmei Chen (ORCID: https://orcid.org/0000-0001-8774-6021)
- Tingting He (ORCID: https://orcid.org/0000-0002-6127-852X)
- Xiaoyan Zhan (ORCID: https://orcid.org/0000-0002-2446-5967)
- Fengyi Li (ORCID: https://orcid.org/0000-0002-2717-4559)
- Junling Cao
- Zhaofang Bai
- Tingming Shen
- Ye Luo
- Xiaohe Xiao
Institutions
- Jiangxi University of Traditional Chinese Medicine (CN)
- Hunan University of Traditional Chinese Medicine (CN)
- Beijing University of Chinese Medicine (CN)
- Capital Medical University (CN)
- Chinese PLA General Hospital (CN)
- Ningde Normal University (CN)
- First Affiliated Hospital of Henan University of Traditional Chinese Medicine (CN)
- Beijing Friendship Hospital (CN)
- Chinese People's Liberation Army (CN)
- State Key Laboratory of Kidney Diseases
Publication Details
- Journal
- Acta Pharmaceutica Sinica B
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1016/j.apsb.2024.12.024
- Citations
- 6
- Primary Topic
- Traditional Chinese Medicine Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.30
Funders
- Yale University
- National Natural Science Foundation of China
- Beijing University of Chinese Medicine
- Chinese Academy of Engineering
- U.S. Food and Drug Administration